Ocata bought by Astellas of Japan: initial perspectives on end of an era

Astellas

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul […]

Ocata bought by Astellas of Japan: initial perspectives on end of an era Read More »